
PTC Therapeutics appoints Tuyen Ong as chief medical officer
pharmafile | April 28, 2016 | Appointment | Business Services, Research and Development |Â Â Â
PTC Therapeutics (Nasdaq: PTCT) has named Tuyen Ong chief medical officer.
He succeeds Robert Spiegel who will remain with the company in a consulting role.
Ong joined PTC in 2014 as the senior vice president, head of clinical development and translational research.
Stuart Peltz, chief executive of PTC Therapeutics, said: “Tuyen has been a valuable addition to the PTC team, bringing a wealth of industry experience and drug development expertise. He will continue to play an important role in the development of Translarna for rare genetic disorders as well as the advancement of our company pipeline. I thank Bob for his significant contributions to PTC over the last five years. He has worked closely with Tuyen and the entire clinical team in advance of this transition to lay the groundwork to support our future clinical and regulatory milestones.”
Prior to joining PTC in 2014, Ong served as vice president of global clinical development and operations at Valeant Pharmaceuticals (previously Bausch and Lomb). Before that he was associated with Pfizer, developing drugs for diseases with high unmet medical need in various disease areas including respiratory, gastrointestinal, hepatology, and ophthalmology.
Ong holds a medical degree from the University of London and an MBA from New York University Stern School of Business.






